

Patricia E Carreira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1571138/publications.pdf>

Version: 2024-02-01

191
papers

16,518
citations

28190
55
h-index

17055
122
g-index

194
all docs

194
docs citations

194
times ranked

12985
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
2	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1747-1755.	0.5	1,705
3	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1809-1815.	0.5	1,017
4	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.5	794
5	Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 754-763.	0.5	739
6	EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 620-628.	0.5	559
7	Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. <i>Nature Genetics</i> , 2010, 42, 426-429.	9.4	351
8	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 963-974.	5.2	348
9	Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 476-481.	0.5	330
10	Overexpression of the Cytokine BAFF and Autoimmunity Risk. <i>New England Journal of Medicine</i> , 2017, 376, 1615-1626.	13.9	301
11	Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1355-1360.	0.5	275
12	Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 218-221.	0.5	214
13	A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. <i>Kidney International</i> , 2019, 95, 219-231.	2.6	208
14	Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. <i>PLoS Genetics</i> , 2011, 7, e1002178.	1.5	201
15	ImmunoChip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	2.6	182
16	The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. <i>Lancet Rheumatology</i> , 2020, 2, e71-e83.	2.2	182
17	Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database. <i>Journal of Rheumatology</i> , 2010, 37, 1488-1501.	1.0	161
18	Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. <i>PLoS ONE</i> , 2016, 11, e0163894.	1.1	158

#	ARTICLE	IF	CITATIONS
19	Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation. <i>Arthritis and Rheumatism</i> , 2012, 64, 1653-1664.	6.7	145
20	Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. <i>Arthritis and Rheumatology</i> , 2017, 69, 1067-1077.	2.9	139
21	Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. <i>Arthritis and Rheumatism</i> , 1999, 42, 989-992.	6.7	133
22	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.5	132
23	Replication of recently identified systemic lupus erythematosus genetic associations: a case-control study. <i>Arthritis Research and Therapy</i> , 2009, 11, R69.	1.6	131
24	Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 22-27.	1.6	123
25	Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis—Results from the International Scleroderma Renal Crisis Survey. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 666-672.	1.6	115
26	An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1433-1439.	0.5	111
27	Digital ulcers predict a worse disease course in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 681-686.	0.5	111
28	Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1788-1792.	0.5	107
29	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1207-1218.	0.5	107
30	Association of PDCD1 with susceptibility to systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 2590-2597.	6.7	106
31	A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. <i>Human Molecular Genetics</i> , 2013, 22, 4021-4029.	1.4	104
32	Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2018, 20, 100.	1.6	102
33	Nailfold capillaroscopy in systemic sclerosis: Data from the EULAR scleroderma trials and research (EUSTAR) database. <i>Microvascular Research</i> , 2013, 89, 122-128.	1.1	101
34	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. <i>Thorax</i> , 2014, 69, 436-444.	2.7	100
35	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. <i>Nature Communications</i> , 2019, 10, 4955.	5.8	100
36	Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. <i>Lupus</i> , 2012, 21, 1063-1076.	0.8	98

#	ARTICLE	IF	CITATIONS
37	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Human Molecular Genetics, 2012, 21, 2825-2835.	1.4	98
38	Urine metabolome profiling of immune-mediated inflammatory diseases. BMC Medicine, 2016, 14, 133.	2.3	97
39	BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. Annals of the Rheumatic Diseases, 2010, 69, 700-705.	0.5	96
40	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Annals of the Rheumatic Diseases, 2015, 74, 1124-1131.	0.5	96
41	Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity, 2006, 39, 205-215.	1.2	93
42	Efficacy of Anakinra in Refractory Adult-Onset Still's Disease. Medicine (United States), 2015, 94, e1554.	0.4	93
43	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Annals of the Rheumatic Diseases, 2016, 75, 103-109.	0.5	93
44	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Annals of the Rheumatic Diseases, 2016, 75, 163-169.	0.5	82
45	Validation of potential classification criteria for systemic sclerosis. Arthritis Care and Research, 2012, 64, 358-367.	1.5	77
46	A rare polymorphism in the gene for Tollâ€like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. Arthritis and Rheumatism, 2012, 64, 264-271.	6.7	77
47	Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Annals of the Rheumatic Diseases, 2011, 70, 454-462.	0.5	75
48	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	2.9	75
49	A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Human Molecular Genetics, 2012, 21, 926-933.	1.4	74
50	Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study. Journal of Rheumatology, 2014, 41, 99-105.	1.0	73
51	Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. Annals of the Rheumatic Diseases, 2016, 75, 1743-1748.	0.5	68
52	Keratinocyte apoptosis and p53 expression in cutaneous lupus and dermatomyositis. , 1999, 188, 63-68.		64
53	A replication study confirms the association of <i>TNFSF4 (OX40L)</i> polymorphisms with systemic sclerosis in a large European cohort. Annals of the Rheumatic Diseases, 2011, 70, 638-641.	0.5	63
54	Survival, Causes of Death, and Risk Factors Associated With Mortality in Spanish Systemic Sclerosis Patients: Results From a Single University Hospital. Seminars in Arthritis and Rheumatism, 2010, 39, 285-293.	1.6	62

#	ARTICLE	IF	CITATIONS
55	Novel identification of the <i>IRF7</i> region as an anticentromere autoantibody propensity locus in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 114-119.	0.5	62
56	Opposed independent effects and epistasis in the complex association of <i>IRF5</i> to SLE. <i>Genes and Immunity</i> , 2007, 8, 429-438.	2.2	58
57	A combined large-scale meta-analysis identifies <i>COG6</i> as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 286-294.	0.5	58
58	Confirmation of <i>TNIP1</i> but not <i>RHOB</i> and <i>PSORS1C1</i> as systemic sclerosis risk factors in a large independent replication study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 602-607.	0.5	56
59	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1285-1292.	0.5	56
60	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	0.9	53
61	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. <i>Rheumatology</i> , 2018, 57, 1623-1631.	0.9	53
62	New insight on the <i>Xq28</i> association with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 2032-2038.	0.5	52
63	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	2.4	52
64	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.5	50
65	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , 2012, 64, 351-357.	1.5	49
66	Association of a non-synonymous single-nucleotide polymorphism of DNASEI with SLE susceptibility. <i>Rheumatology</i> , 2006, 45, 819-823.	0.9	48
67	Comprehensive Description of Clinical Characteristics of a Large Systemic Lupus Erythematosus Cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) With Emphasis on Complete Versus Incomplete Lupus Differences. <i>Medicine (United States)</i> , 2015, 94, e267.	0.4	48
68	Analysis of Class II human leucocyte antigens in Italian and Spanish systemic sclerosis. <i>Rheumatology</i> , 2012, 51, 52-59.	0.9	46
69	Brief Report: <i>IRF4</i> Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies. <i>Arthritis and Rheumatology</i> , 2016, 68, 2338-2344.	2.9	46
70	Clonally expanded lymphocytes in the minor salivary glands of sjögren's syndrome patients without lymphoproliferative disease. <i>Arthritis and Rheumatism</i> , 1994, 37, 1441-1444.	6.7	44
71	Reconciling Healthcare Professional and Patient Perspectives in the Development of Disease Activity and Response Criteria in Connective Tissue Disease-related Interstitial Lung Diseases. <i>Journal of Rheumatology</i> , 2014, 41, 792-798.	1.0	43
72	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. <i>Autoimmunity Reviews</i> , 2020, 19, 102452.	2.5	43

#	ARTICLE	IF	CITATIONS
73	European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 629-634.	0.5	41
74	A profibrotic role for thymic stromal lymphopoietin in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 2018-2023.	0.5	41
75	Influence of <i>TYK2</i> in systemic sclerosis susceptibility: a new <i>locus</i> in the IL-12 pathway. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1521-1526.	0.5	41
76	Late-onset systemic sclerosis—a systematic survey of the EULAR scleroderma trials and research group database. <i>Rheumatology</i> , 2011, 50, 161-165.	0.9	39
77	The Systemic Lupus Erythematosus IRF5 Risk Haplotype Is Associated with Systemic Sclerosis. <i>PLoS ONE</i> , 2013, 8, e54419.	1.1	38
78	Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases. <i>Rheumatology</i> , 1998, 37, 773-778.	0.9	37
79	Comparison of Baseline Characteristics and Survival Between Patients With Idiopathic and Connective Tissue Disease-related Pulmonary Arterial Hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 621-627.	0.3	37
80	A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. <i>Arthritis Research and Therapy</i> , 2014, 16, R6.	1.6	37
81	Influence of the <i>IL6</i> Gene in Susceptibility to Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 2294-2302.	1.0	34
82	Apoptosis and Proliferation of Fibroblasts During Postnatal Skin Development and Scleroderma in the Tight-skin Mouse. <i>Journal of Histochemistry and Cytochemistry</i> , 1997, 45, 711-719.	1.3	33
83	A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R85.	1.6	32
84	Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 238-245.	0.7	32
85	Cardiovascular disease in immune-mediated inflammatory diseases. <i>Medicine (United States)</i> , 2017, 96, e7308.	0.4	32
86	Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain. <i>Rheumatology International</i> , 2017, 37, 1853-1861.	1.5	32
87	The three most common CARD15 mutations associated with Crohn's disease and the chromosome 16 susceptibility locus for systemic lupus erythematosus. <i>British Journal of Rheumatology</i> , 2003, 42, 570-574.	2.5	31
88	Validation of the Self-Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2016, 68, 1195-1200.	1.5	31
89	Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2016, 16, 137-140.	0.9	31
90	Implication of <i>IL-2/IL-21</i> region in systemic sclerosis genetic susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1233-1238.	0.5	30

#	ARTICLE	IF	CITATIONS
91	Evidence that deletion at FCGR3B is a risk factor for systemic sclerosis. <i>Genes and Immunity</i> , 2012, 13, 458-460.	2.2	29
92	Identification of <i>IL12RB1</i> as a Novel Systemic Sclerosis Susceptibility Locus. <i>Arthritis and Rheumatology</i> , 2014, 66, 3521-3523.	2.9	29
93	Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review. <i>Rheumatology International</i> , 2015, 35, 1447-1459.	1.5	29
94	Further Evidence of Subphenotype Association with Systemic Lupus Erythematosus Susceptibility Loci: A European Cases Only Study. <i>PLoS ONE</i> , 2012, 7, e45356.	1.1	28
95	There is a need for new systemic sclerosis subset criteria. A content analytic approach. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 62-70.	0.6	28
96	Overlap myositis, a distinct entity beyond primary inflammatory myositis: A retrospective analysis of a large cohort from the REMICAM registry. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1393-1401.	0.9	28
97	Polymorphism of the interleukin-1 receptor antagonist gene: A factor in susceptibility to rheumatoid arthritis in a Spanish population. <i>Arthritis and Rheumatism</i> , 2005, 52, 3015-3019.	6.7	27
98	Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population. <i>Rheumatology</i> , 2011, 50, 1976-1981.	0.9	27
99	Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. <i>Clinical Rheumatology</i> , 2019, 38, 803-815.	1.0	27
100	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. <i>Rheumatology</i> , 2020, 59, 1684-1694.	0.9	27
101	C-reactive protein (CRP) levels in systemic lupus erythematosus (SLE). <i>Clinical Rheumatology</i> , 1986, 5, 66-69.	1.0	26
102	Subcutaneous Nodular Amyloidosis in Sjögren's Syndrome. <i>Scandinavian Journal of Rheumatology</i> , 1993, 22, 250-251.	0.6	26
103	Nailfold capillaroscopy in Behçet's disease, analysis of 128 patients. <i>Clinical Rheumatology</i> , 2009, 28, 603-605.	1.0	26
104	Identification of a Untranslated Genetic Variant of <i>RARB</i> Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 351-360.	2.9	26
105	Survival of patients with colorectal carcinoma. , 1999, 86, 1675-1681.		25
106	Pulmonary hypertension in autoimmune rheumatic diseases. <i>Autoimmunity Reviews</i> , 2004, 3, 313-320.	2.5	25
107	Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. <i>Arthritis Research and Therapy</i> , 2014, 16, R66.	1.6	25
108	Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. <i>Rheumatology</i> , 2015, 54, 1262-1269.	0.9	25

#	ARTICLE	IF	CITATIONS
109	An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2017, 44, 1453-1457.	1.0	25
110	Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. <i>PLoS ONE</i> , 2018, 13, e0189498.	1.1	25
111	Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. <i>Journal of Psychosomatic Research</i> , 2020, 139, 110262.	1.2	25
112	The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis. <i>Genes and Immunity</i> , 2012, 13, 191-196.	2.2	23
113	Lack of Association between ABO, PPAP2B, ADAMST7, PIK3CG, and EDNRA and Carotid Intima-Media Thickness, Carotid Plaques, and Cardiovascular Disease in Patients with Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2014, 2014, 1-6.	1.4	23
114	Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis. <i>Scientific Reports</i> , 2016, 6, 31979.	1.6	23
115	Using Optimal Test Assembly Methods for Shortening Patient-Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2016, 68, 1704-1713.	1.5	23
116	Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Rheumatology</i> , 2013, 52, 560-567.	0.9	22
117	FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. <i>Pharmacogenomics</i> , 2015, 16, 333-345.	0.6	21
118	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. <i>Journal of Psychosomatic Research</i> , 2020, 135, 110132.	1.2	21
119	An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S47-54.	0.4	21
120	Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. <i>Arthritis Research and Therapy</i> , 2020, 22, 257.	1.6	20
121	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 4786-4796.	0.9	20
122	Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, R146.	1.6	19
123	Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept. <i>PLoS ONE</i> , 2019, 14, e0213073.	1.1	19
124	Ten years EULAR Scleroderma Research and Trials (EUSTAR): what has been achieved?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 324-327.	0.5	18
125	Validation of the Social Appearance Anxiety Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1557-1562.	1.5	17
126	Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Scientific Reports</i> , 2018, 8, 8195.	1.6	17

#	ARTICLE	IF	CITATIONS
127	Chronic intestinal pseudo-obstruction: a diagnosis to be considered. Revista Espanola De Enfermedades Digestivas, 2009, 101, 336-42.	0.1	17
128	Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis. Annals of the Rheumatic Diseases, 2011, 70, 2050-2052.	0.5	15
129	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. Arthritis and Rheumatology, 2018, 70, 1829-1834.	2.9	15
130	SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients. Rheumatology, 2021, 60, 2946-2957.	0.9	15
131	Genome-wide pathway analysis identifies VEGF pathway association with oral ulceration in systemic lupus erythematosus. Arthritis Research and Therapy, 2017, 19, 138.	1.6	14
132	Registro de pacientes con miopatía inflamatoria de la Sociedad Madrileña de Reumatología: análisis descriptivo. Reumatología Clínica, 2017, 13, 331-337.	0.2	14
133	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. Rheumatology, 2020, 59, 2016-2023.	0.9	14
134	Association of Systemic Lupus Erythematosus Clinical Features with European Population Genetic Substructure. PLoS ONE, 2011, 6, e29033.	1.1	14
135	Study of DNASE I gene polymorphisms in systemic lupus erythematosus susceptibility. Annals of the Rheumatic Diseases, 2006, 66, 560-561.	0.5	13
136	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. Microvascular Research, 2015, 102, 19-24.	1.1	13
137	Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. PLoS ONE, 2018, 13, e0196793.	1.1	13
138	Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database. Clinical and Experimental Rheumatology, 2015, 33, S75-9.	0.4	13
139	SMAD3 rs17228212 Gene Polymorphism Is Associated with Reduced Risk to Cerebrovascular Accidents and Subclinical Atherosclerosis in Anti-CCP Negative Spanish Rheumatoid Arthritis Patients. PLoS ONE, 2013, 8, e77695.	1.1	12
140	Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis. Scientific Reports, 2017, 7, 40303.	1.6	12
141	Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis. Arthritis Research and Therapy, 2012, 14, R154.	1.6	11
142	Lack of replication of higher genetic risk load in men than in women with systemic lupus erythematosus. Arthritis Research and Therapy, 2014, 16, R128.	1.6	11
143	'Quality of pain' in systemic sclerosis. Rheumatology, 2006, 45, 1185-1186.	0.9	10
144	KCNA5 gene is not confirmed as a systemic sclerosis-related pulmonary arterial hypertension genetic susceptibility factor. Arthritis Research and Therapy, 2012, 14, R273.	1.6	10

#	ARTICLE	IF	CITATIONS
145	Validation of the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for systemic sclerosis in patients from a capillaroscopy clinic. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 350-355.	1.6	10
146	Osteoprotegerin CGA Haplotype Protection against Cerebrovascular Complications in Anti-CCP Negative Patients with Rheumatoid Arthritis. <i>PLoS ONE</i> , 2014, 9, e106823.	1.1	10
147	Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (SclerolD) questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 507-515.	0.5	10
148	Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR). <i>Journal of Rheumatology</i> , 2010, 37, 1673-1679.	1.0	9
149	The 11q23.3 genomic region “rs964184” is associated with cardiovascular disease in patients with rheumatoid arthritis. <i>Tissue Antigens</i> , 2013, 82, 344-347.	1.0	9
150	The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: results from a nationwide cohort in Spain (LESIMAB). <i>Lupus</i> , 2014, 23, 1014-1022.	0.8	9
151	Rheumatoid arthritis response to treatment across IgG1 allotype “anti-TNF incompatibility: a case-only study. <i>Arthritis Research and Therapy</i> , 2015, 17, 63.	1.6	9
152	Lack of Association between JAK3 Gene Polymorphisms and Cardiovascular Disease in Spanish Patients with Rheumatoid Arthritis. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	9
153	An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first symptoms and auto-antibodies: derivation and validation. <i>Rheumatology</i> , 2016, 55, 2023-2032.	0.9	9
154	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. <i>Journal of Psychosomatic Research</i> , 2021, 140, 110314.	1.2	9
155	Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study. <i>Lancet Rheumatology</i> , The, 2021, 3, e844-e854.	2.2	9
156	Polymorphisms in the Interleukin 4, Interleukin 13, and Corresponding Receptor Genes Are Not Associated with Systemic Sclerosis and Do Not Influence Gene Expression. <i>Journal of Rheumatology</i> , 2012, 39, 112-118.	1.0	8
157	Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: a case-control study. <i>Arthritis Research and Therapy</i> , 2012, 14, R94.	1.6	8
158	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1646-1652.	1.5	8
159	LAUDES Study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients. <i>Rheumatology International</i> , 2019, 39, 1875-1882.	1.5	8
160	Prediction of organ involvement and survival in systemic sclerosis patients in the first 5 years from diagnosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 57-65.	1.0	8
161	Evidence of telomere attrition and a potential role for DNA damage in systemic sclerosis. <i>Immunity and Ageing</i> , 2022, 19, 7.	1.8	8
162	2013 ACR/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 870-876.	1.6	7

#	ARTICLE	IF	CITATIONS
163	Multicenter Registry on Inflammatory Myositis From the Rheumatology Society in Madrid, Spain: Descriptive Analysis. <i>Reumatología Clínica (English Edition)</i> , 2017, 13, 331-337.	0.2	6
164	Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature. <i>Reumatología Clínica</i> , 2019, 15, 34-42.	0.2	6
165	Determinants of health-related quality of life in a multinational systemic sclerosis inception cohort. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 53-60.	0.4	6
166	Clinical Characteristics of Juvenile Idiopathic Inflammatory Myopathy and Comparison With Adult Patients. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e195-e202.	0.5	5
167	Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 1368-1382.	1.3	5
168	The burden of systemic sclerosis in Switzerland – the Swiss systemic sclerosis EUSTAR cohort. <i>Swiss Medical Weekly</i> , 2021, 151, w20528.	0.8	5
169	No evidence of association between functional polymorphisms located within <i>IL6R</i> and <i>IL6ST</i> genes and systemic sclerosis. <i>Tissue Antigens</i> , 2012, 80, 254-258.	1.0	4
170	Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 1300-1310.	1.5	4
171	Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database. <i>Rheumatology</i> , 2021, 61, 213-222.	0.9	4
172	Antifibrotics in systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101671.	1.4	4
173	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. <i>Trials</i> , 2021, 22, 856.	0.7	4
174	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S31-5.	0.4	4
175	Evaluation of a Shared Autoimmune Disease-associated Polymorphism of TRAF6 in Systemic Sclerosis and Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2012, 39, 1275-1279.	1.0	3
176	Single-nucleotide polymorphisms at the 9p21.3 genomic region not associated with the risk of cardiovascular disease in patients with rheumatoid arthritis. <i>Tissue Antigens</i> , 2013, 82, 405-409.	1.0	3
177	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. <i>Body Image</i> , 2017, 20, 99-106.	1.9	3
178	Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 68-75.	0.4	3
179	Non-lymphopenic pneumocystis pneumonia in low-dose methotrexate therapy: An exception to every rule. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101289.	0.2	2
180	Recomendaciones SER sobre prevención de infección en enfermedades reumáticas autoinmunes sistémicas. <i>Reumatología Clínica</i> , 2022, 18, 317-330.	0.2	2

#	ARTICLE	IF	CITATIONS
181	Keratinocyte apoptosis and p53 expression in cutaneous lupus and dermatomyositis. , 1999, 188, 63.		2
182	Profibrotic Role of Inducible Heat Shock Protein 90 α Isoform in Systemic Sclerosis. Journal of Immunology, 2022, 209, 38-48.	0.4	2
183	Inflammation and HIV infection: a friendly connection. Lancet, The, 1996, 348, S24.	6.3	1
184	Tratamiento con oxígeno hiperbárico en el fenómeno de Raynaud y las úlceras digitales asociadas a esclerosis sistémicas. Reumatología Clínica, 2022, 18, 246-248.	0.2	1
185	Recommendations for prevention of infection in systemic autoimmune rheumatic diseases. Reumatología Clínica (English Edition), 2022, 18, 317-330.	0.2	1
186	Treatment of Raynaud phenomenon and ischemic ulcers associated to systemic sclerosis with hyperbaric oxygen. Reumatología Clínica (English Edition), 2021, , .	0.2	1
187	Antibodies to extractable cellular antigens in Spanish systemic lupus erythematosus (SLE) patients. Clinical Rheumatology, 1987, 6, 80-83.	1.0	0
188	Lack of association between the MHC linked OTF3 gene and systemic lupus erythematosus. Lupus, 1995, 4, 390-392.	0.8	0
189	FRI0348...USE OF INTRAVENOUS IMMUNOGLOBULIN THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS: A SPANISH MULTICENTER EXPERIENCE. , 2019, , .		0
190	OP0212...DIGESTIVE INVOLVEMENT IN PATIENTS WITH PRIMARY SJÖGREN SYNDROME FROM THE SJOGRENSER SPANISH REGISTRY. , 2019, , .		0
191	The role of the NLRP1 gene in systemic sclerosis: a replication study. Clinical and Experimental Rheumatology, 2013, 31, 187-8.	0.4	0